Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Vertex Pharmaceuticals
(NQ:
VRTX
)
455.48
-1.88 (-0.41%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 5, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Vertex Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
Next >
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions
Today 7:01 EST
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex to Participate in the Citi’s 2025 Global Healthcare Conference on December 3
November 19, 2025
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week
November 08, 2025
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Reports Third Quarter 2025 Financial Results
November 03, 2025
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex to Participate in the UBS Global Healthcare Conference on November 11
October 27, 2025
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK® at the North American Cystic Fibrosis Conference
October 23, 2025
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week
October 17, 2025
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex to Announce Third Quarter 2025 Financial Results on November 3rd
October 06, 2025
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Announces Key Advancements Across Kidney Portfolio
September 25, 2025
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Partners with Basketball World Champion Jayson Tatum to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe-Acute Pain
September 23, 2025
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia and Sickle Cell Disease in Italy
September 18, 2025
From
Vertex Pharmaceuticals
Via
Business Wire
Vertex Scientists Awarded the 2025 Lasker~DeBakey Clinical Medical Research Award for Pioneering Discoveries in Cystic Fibrosis
September 11, 2025
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex to Participate in Upcoming September Investor Conferences
August 20, 2025
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Reports Second Quarter 2025 Financial Results
August 04, 2025
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain
August 04, 2025
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Named a Premier, Inc. Breakthroughs Innovation Celebration Winner for JOURNAVX™, a First-in-Class Non-Opioid Treatment for Adults With Moderate-to-Severe Acute Pain
July 14, 2025
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
July 09, 2025
Via
Investor Brand Network
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
July 09, 2025
EQNX::TICKER_START (NYSE:CLDI),(NASDAQ:VRTX),(NASDAQ:IBRX),(NASDAQ:CRSP),(NASDAQ:CTMX) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Death
Vertex to Announce Second Quarter 2025 Financial Results on August 4th
July 08, 2025
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
July 07, 2025
EQNX::TICKER_START (NYSE:CLDI),(NASDAQ:REGN),(NASDAQ:VRTX),(OTCQX:RHHBY),(NYSE:MRK) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Death
Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
June 23, 2025
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions
June 20, 2025
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference
June 06, 2025
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex to Participate in Upcoming Investor Conferences
May 15, 2025
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Reports First Quarter 2025 Financial Results
May 05, 2025
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis
April 11, 2025
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex to Announce First Quarter 2025 Financial Results on May 5th
April 07, 2025
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Announces Program Updates for Type 1 Diabetes Portfolio
March 28, 2025
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex to Participate in Upcoming March Investor Conferences
February 18, 2025
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
February 10, 2025
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit